ORIC - ORIC Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

495.3M

Cash

316.8M

Avg Qtr Burn

-23.81M

Short % of Float

31.45%

Insider Ownership

9.55%

Institutional Own.

96.19%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORIC-114 (EGFR/HER2 Inhibitor) Details Solid tumor/s, Advanced malignancies, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-533 (CD73 Inhibitor) Details Multiple myeloma, Cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-944 (PRC2 inhibitor) Details Prostate cancer, Cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 (Glucocorticoid Receptor Antagonist) + Xtandi (enzalutamide) Details Prostate cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 (Glucocorticoid Receptor Antagonist) and nab-paclitaxel Details Solid tumor/s, Muscle control disorder, Spasticity, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.